Solventum's "Value Unlock" Is Really a Fire Sale of Its Own Future

Solventum is a company that exists to be taken apart. Fresh off selling one business, the 3M spinoff is now collecting initial offers for another per an Axios Pro report-its Health Information Systems unit, the software that does medical coding, billing and documentation for hospitals. The business is being marketed at $5.5 billion to $7 billion. Against a whole-company enterprise value that Ainvest data puts near $19 billion, that is one division priced at roughly a third of everything.

If you hold this stock, you may be a shareholder by inheritance rather than by choice: the shares arrived in 2024, when 3M spun its health-care business off, and landed in your account with no decision attached. You have been told this is a feature, not a bug. The whole "spinoff revaluation play" runs on the promise that dismantling Solventum in pieces reveals how cheap the shell really is. The stock has already done the early part of that work, climbing off the low $60s to the mid-$80s. The good news is real. That is precisely what makes it dangerous.

Now follow the money. Solventum has already sold its purification and filtration unit to Thermo Fisher for $4.1 billion in cash. Add the HIS sale to that and the company is raising, or has raised, roughly $10 billion for two of its four divisions-well over half its entire market value of about $14.5 billion. Meanwhile its total revenue is roughly flat year over year. The rising earnings story is not coming from a growing customer base. It is coming from selling pieces and calling the arithmetic revaluation.

The dangerous part of the deal is not that Solventum is selling. It is what it is selling. HIS is the growth story-the division management hypes with AI vocabulary, touting autonomous coding, AI-driven documentation and its "360 Encompass" platform. It is the software asset carrying the premium multiple. Selling it hands that upside to a buyer who will lever it up, while Solventum keeps what is left: wound care, sterilization, dental-the mature products with the lowest multiple. Management calls the remnant the "true medtech company." That is corporate language for "we sold the interesting half and kept the slow half." The cash will mostly repay debt-the spinoff arrived carrying net debt that Ainvest data puts near $4.7 billion-rather than fund new growth, so the operating base that produced organic growth is walking out the door alongside the leverage.

This is a reflexive loop with an unknown clock, and it only compounds while two things stay true at once: buyers must keep writing checks, and the market must keep pricing the leftover sum of parts higher than the whole, even as every sale shrinks the cash-generating base and concentrates the remaining profit into fewer, slower businesses.

So the offers themselves are the signal. If HIS draws a strategic buyer near $7 billion, the thesis is validated: the parts really were worth more apart, and the leftover "pure play" can re-rate up. Watch that. And watch the opposite case. If the offers come in light, or drag, that tells you the software-style premium was the entire game-and that the "unlock" was a hope someone else priced more skeptically. Then you are left owning the slow half, at a multiple the market re-prices the moment the exciting asset is no longer holding it up.

You were told the sum of the pieces exceeds the whole. That is only true for as long as someone keeps paying for the pieces. The comfort that once made this stock feel cheap-the belief that the parts out-value the shell-dies the day the buyers stop showing up.